1.	Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: NCI, Other Protocol IDs: ACNS0331, COG-ACNS0331, CDR0000365506, NCT00085735
2.	Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 Sponsor: NCI, Other Protocol IDs: ACNS0334, NCI-2009-00338, COG-ACNS0334, CDR0000483683, U10CA098543, NCT00336024
3.	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: ACNS0332, NCI-2009-00336, COG-ACNS0332, CDR0000511991, U10CA098543, R01CA114567, NCT00392327
4.	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: Other Protocol IDs: SJMB03, SJCRH-SJMB03, NCT00085202
5.	A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225C2301, NCT01708174
6.	A Phase I/II Study of the Photon Radiosurgery System Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
7.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
8.	Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
9.	A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
10.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
11.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
12.	Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 12 months to 30 years Sponsor: Pharmaceutical / Industry Protocol IDs: NMTRC 004, NCT01483820
13.	Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 3 to 30 at initial diagnosis Sponsor: Other Protocol IDs: CDR0000069075, CHP-693, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590
14.	High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood Phase: Phase II Type: Treatment Status: Active Age: 10 and under Sponsor: Other Protocol IDs: PNET HR, NCT00180791
15.	Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Phase: Phase II Type: Treatment Status: Active Age: 1 to 25 Sponsor: Other Protocol IDs: NAVE-CYCLO, NCT00180947
16.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
17.	Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Pharmaceutical / Industry Protocol IDs: V0706, NCT00601003
18.	High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: Children Sponsor: Other Protocol IDs: 2005-12-009, NCT00798811
19.	Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours Phase: Phase II Type: Treatment Status: Active Age: 6 months to 20 years Sponsor: Other Protocol IDs: CSET 2008/1378, NCT00918320
20.	Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years Phase: Phase II Type: Treatment Status: Active Age: 5 to 19 Sponsor: Other Protocol IDs: PNET HR+ 5, CSET 1329, NCT00936156
21.	Antineoplaston Therapy in Treating Children With Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
22.	Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
23.	Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma Phase: Phase II Type: Treatment Status: Active Age: 3 to 25 Sponsor: NCI, Other Protocol IDs: 09-361, P01CA021239, NCT01063114
24.	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: NCI-2011-02605, ACNS0821, U10CA098543, COG-ACNS0821, NCT01217437
25.	GDC-0449 in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02546, PBTC-032, U01CA081457, NCT01239316